Skip to main content
. 2019 Oct 22;7(11):E1432–E1441. doi: 10.1055/a-0990-9488

Table 2. Efficacy and safety of EUS-BD for malignant biliary obstruction: cumulative and comparative meta-analysis.

Cumulative data for EUS-BD Comparative data for EUS-BD vs ERCP
Pooled rate (95 % CI) Heterogeneity (I 2 ) Odds ratio (95 % CI) Heterogeneity (I 2 )
Technical success 95 % (95 % CI 91 to 98) 0.00 % 1.30 (95 % CI 0.38 to 4.50) 33.00 %
Clinical success 97 % (95 % CI 93 to 100) 16.70 % 2.32 (95 % CI 0.48 to 11.15) 51.00 %
Total adverse events 19 % (95 % CI 11 to 29) 56.00 % 0.70 (95 % CI 0.24 to 2.03) 70.00 %

  • Pancreatitis

 0 % (95 % CI 0 to 1) 0.00 % 0.17 (95 % CI 0.04 to 0.79) 0.00 %

  • Bile peritonitis

 3 % (95 % CI 0 to 8) 40.19 % 2.91 (95 % CI 0.12 to 72.70) NA *

  • Pneumoperitoneum

 0 % (95 % CI 0 to 2) 0.00 % 1.79 (95 % CI 0.19 to 16.66) 0.00 %

  • Cholangitis

 2 % (95 % CI 0 to 7) 57.58 % 0.74 (95 % CI 0.33 to 1.68) 0.00 %

  • Cholecystitis

 1 % (95 % CI 0 to 5) 25.51 % 0.75 (95 % CI 0.14 to 3.90) 37.00 %

  • Stent migration

 0 % (95 % CI 0 to 2) 0.00 % 0.74 (95 % CI 0.10 to 5.37) 11.00 %

  • Stent dysfunction/occlusion

 0 % (95 % CI 0 to 2) 5.00 % 0.30 (95 % CI 0.06 to 1.47) 0.00 %
Reintervention rate 7 % (95 % CI 2 to 13) 41.49 % 0.23 (95 % CI 0.10 to 0.49) 1.00 %

EUS-BD, endoscopic ultrasound-guided biliary drainage; ERCP, endoscopic retrograde cholangiopancreatography.

*

Heterogeneity unable to be calculated based upon limited events occurring